Immutep Ltd has released a press release.
Immutep receives 2nd IND approval for efti from US FDA
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immutep
- Immutep reports positive TACTI-002 data
- Immutep Activities Report
- Immutep expands Part C of TACTI-002 due to positive data
- INSIGHT-004 clinical trial update
- Immutep announces European patent grant for LAG525 antibody
Later from Immutep
- Immutep reports supportive efficacy data from AIPAC study
- Immutep AIPAC Ph2b Clinical Results & Update Webcast Slides
- EOC Pharma confirms plans to advance Efti in China for MBC
- Immutep presents TACTI-002 data at AACR Virtual Meeting
- Immutep advances its LAG-3 agonist for autoimmune diseases
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep